{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:03Z","timestamp":1790612103915,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.arbres.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,5,31]],"date-time":"2020-05-31T07:17:42Z","timestamp":1590909462000},"page":"599-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Quilot\u00f3rax espont\u00e1neo secundario a dasatinib"],"prefix":"10.1016","volume":"56","author":[{"given":"Virginia","family":"Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Va\u00f1es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Castell\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eusebi","family":"Chiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2020.05.001_bib0080","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arbres.2020.05.001_bib0085","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or High-Dose Imatinib for Chronic-Phase Chronic Myeloid Leukemia After Failure of First-Line Imatinib: A Randomized Phase 2 Trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.arbres.2020.05.001_bib0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, Outcomes, and Risk Factors of Pleural Effusion in Patients Receiving Dasatinib Therapy for Philadelphia Chromosome-Positive Leukemia","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.arbres.2020.05.001_bib0095","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4274\/tjh.2012.0196","article-title":"Dasatinib-related Chylothorax","volume":"32","author":"Huang","year":"2015","journal-title":"Turk J Haematol."},{"key":"10.1016\/j.arbres.2020.05.001_bib0100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/1817-1737.191871","article-title":"Dasatinib-induced Pleural Effusion: Chylothorax, an Option to Consider","volume":"11","author":"Ferreiro","year":"2016","journal-title":"Ann Thorac Med."},{"key":"10.1016\/j.arbres.2020.05.001_bib0105","doi-asserted-by":"crossref","first-page":"571A","DOI":"10.1016\/j.chest.2016.08.660","article-title":"Chylothorax and PAH After Treatment With Dasatinib: A Case Report","volume":"150","author":"Chua","year":"2016","journal-title":"Chest."},{"key":"10.1016\/j.arbres.2020.05.001_bib0110","first-page":"71","article-title":"Dasatinib-induced Chylothorax in Chronic Myeloid Leukemia","volume":"30","author":"Baloch","year":"2017","journal-title":"Proc (Bayl Univ Med Cent)."},{"key":"10.1016\/j.arbres.2020.05.001_bib0115","doi-asserted-by":"crossref","first-page":"e231653","DOI":"10.1136\/bcr-2019-231653","article-title":"Chylothorax: Complication Attributed to Dasatinib Use","volume":"12","author":"Al-Abcha","year":"2019","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.arbres.2020.05.001_bib0120","article-title":"Dasatinib-induced Chylothorax in Chronic Myelogenous Leukemia in Pediatric Patient: Report of a Case and Review of Literature","author":"Hickman","year":"2019","journal-title":"J Pediatr Hematol Oncol."},{"key":"10.1016\/j.arbres.2020.05.001_bib0125","doi-asserted-by":"crossref","first-page":"e0122555","DOI":"10.1371\/journal.pone.0122555","article-title":"Growth-factor-driven Rescue to Receptor Tyrosine Kinase (RTK) Inhibitors Through Akt and Erk Phosphorylation in Pediatric Low Grade Astrocytoma and Ependymoma","volume":"10","author":"Sie","year":"2015","journal-title":"PLoS One."},{"key":"10.1016\/j.arbres.2020.05.001_bib0130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2004.08.034","article-title":"PDGF-BB Induces Intratumoral Lymphangiogenesis and Promotes Lymphatic Metastasis","volume":"6","author":"Cao","year":"2004","journal-title":"Cancer Cell."},{"key":"10.1016\/j.arbres.2020.05.001_bib0135","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung Abnormalities After Dasatinib Treatment for Chronic Myeloid Leukemia: A Case Series","volume":"176","author":"Bergeron","year":"2007","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.arbres.2020.05.001_bib0140","doi-asserted-by":"crossref","first-page":"1701096","DOI":"10.1183\/13993003.01096-2017","article-title":"Dasatinib Increases Endothelial Permeability Leading to Pleural Effusion","volume":"51","author":"Phan","year":"2018","journal-title":"Eur Respir J."},{"key":"10.1016\/j.arbres.2020.05.001_bib0145","series-title":"Textbook of pleural diseases","article-title":"Effusions from lymphatic disruptions","author":"Hillerdall","year":"2003"},{"key":"10.1016\/j.arbres.2020.05.001_bib0150","first-page":"1348","article-title":"[Chylothorax Related with Dasatinib in the Treatment of Chronic Myeloid Leukemia: Report of 3 Cases]","volume":"24","author":"Yang","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi."}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289620301344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289620301344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:39:00Z","timestamp":1759531140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289620301344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0300289620301344"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2020.05.001","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quilot\u00f3rax espont\u00e1neo secundario a dasatinib","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}